ATA Guidelines Tools

Anaplastic Thyroid Cancer ATA 2021

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: http://eguideline.guidelinecentral.com/i/1441026

Contents of this Issue

Navigation

Page 27 of 27

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2021 All rights reserved ATAANA04213a Disclaimer is pocket guide attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice, but also is applicable to providers at all levels. is pocket guide should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Source Bible KC, Kebebew E, Brierley JD, et al. American yroid Association Anaplastic yroid Cancer Guidelines Task Force. 2021 American yroid Association Guidelines for Management of Patients with Anaplastic yroid Cancer. yroid 2021;31(3):337-386 American yroid Association Headquarters 2000 Duke Street, Suite 300 • Alexandria, VA 22314 Phone: 703.998.8890 • Fax: 703.998.8893 • www.thyroid.org Physician referral, patient resources available online in English and Spanish. Abbreviations ATC, anaplastic thyroid cancer; AUC, area under the curve; BUN, blood urea nitrogen; CR, complete response; CT, computed tomography, DTC, differentiated thyroid cancer; 18 F FDG PET, 18 F fluorodeoxyglucose positron emission tomography; FNA, fine needle aspiration; Gy, Gray; IHC, immunohistochemistry; IMRT, intensity-modulated radiation therapy; MRI, magnetic resonance imaging ; MTC, medullary thyroid cancer; PD, progressive disease; PDTC, poorly differentiated thyroid cancer; PR, partial response; R, negative gross margin resection; R0, negative microscopic and gross margin resection; SCC, squamous cell carcinoma; SC, stable disease; T4, thyroxine; TSH, thyroid stimulating hormone.

Articles in this issue

Links on this page

Archives of this issue

view archives of ATA Guidelines Tools - Anaplastic Thyroid Cancer ATA 2021